Apollomics initiates dispute process with Launxp over unpaid $3.8 million vebreltinib license fee

Apollomics Inc. Class A

APLM

0.00

Apollomics initiated a contractually required dispute-resolution process with Launxp on June 18 over termination of a vebreltinib Asia license.
Termination took effect June 11, citing Launxp’s alleged failure to pay the remaining USD 3.8 million upfront balance plus interest.
Process starts with 30-day internal talks, then escalates to executive officers if unresolved.
Apollomics is seeking recovery of the USD 3.8 million plus interest, while defending its termination and rights.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apollomics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-281262), on June 24, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.